Recent Updates
Recently added Catalysts
CRDF Positive Sentiment Score: 75/100

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Thursday, August 28, 2025 2 min read
Key Takeaway: Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm, has announced its participation in three upcoming investor conferences in September 2025. These events include the Wells Fargo 20th Annual Healthcare Conference, the Morgan Stanley 23rd Annual Global Healthcare Conference, and the H.C. Wainwright 27th Annual Global Investment Conference. The participation reflects the company's strategic efforts to engage with investors while showcasing its advancements in developing novel therapies targeting multiple cancer indications.

Market Sentiment Analysis

POSITIVE FACTORS

  • Cardiff Oncology is increasing its visibility by participating in three notable investor conferences.
  • The company is well-positioned with its innovative therapies targeting various cancers.
  • Senior management's involvement signals confidence in the company's growth and potential.

Full Press Release Details

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025.
Details of the events can be found below.
Wells Fargo 20th Annual Healthcare Conference
Format: 1x1 Meetings
Location: Encore Boston Harbor, Everett, MA
Morgan Stanley 23rd Annual Global Healthcare Conference
Format: 1x1 Meetings
Location: Sheraton New York Times Square, New York, NY
H.C. Wainwright 27th Annual Global Investment Conference
Format: Fireside Chat and 1x1 Meetings
Presenter: Mark Erlander, CEO
Location: Lotte New York Palace Hotel, New York, NY
Interested parties can register for and access the live webcast for the H.C. Wainwright conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
Chief Financial Officer
jlevine@cardiffoncology.com
Kiki@gilmartinir.com
Taft Communications, a division of RF|Binder
meghan.bianco@rfbinder.com

Tags

Frequently Asked Questions

What company is participating in September 2025 conferences?

Cardiff Oncology, Inc. is participating in the investor conferences.

Where will the Wells Fargo conference be held?

The Wells Fargo Annual Healthcare Conference will be at Encore Boston Harbor, MA.

Who is presenting at the H.C. Wainwright conference?

Mark Erlander, CEO of Cardiff Oncology, will present at the conference.

What is Cardiff Oncology's main drug development focus?

The company focuses on PLK1 inhibition to develop cancer therapies.

How can I access the H.C. Wainwright conference webcast?

Visit Cardiff Oncology's website under the 'Events' section to access the webcast.

Tags: CRDF Viatris Investor Conferences Healthcare biotechnology cancer therapies investor conferences clinical-stage
Last updated: Aug 28, 2025